JP5167149B2 - 白血病の診断および治療ターゲット - Google Patents

白血病の診断および治療ターゲット Download PDF

Info

Publication number
JP5167149B2
JP5167149B2 JP2008551261A JP2008551261A JP5167149B2 JP 5167149 B2 JP5167149 B2 JP 5167149B2 JP 2008551261 A JP2008551261 A JP 2008551261A JP 2008551261 A JP2008551261 A JP 2008551261A JP 5167149 B2 JP5167149 B2 JP 5167149B2
Authority
JP
Japan
Prior art keywords
calm
hoxa5
fusion protein
dot1l
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008551261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524051A (ja
JP2009524051A5 (enExample
Inventor
チャン，イー
由紀 岡田
Original Assignee
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル filed Critical ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Publication of JP2009524051A publication Critical patent/JP2009524051A/ja
Publication of JP2009524051A5 publication Critical patent/JP2009524051A5/ja
Application granted granted Critical
Publication of JP5167149B2 publication Critical patent/JP5167149B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2008551261A 2006-01-20 2006-12-06 白血病の診断および治療ターゲット Expired - Fee Related JP5167149B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76070906P 2006-01-20 2006-01-20
US60/760,709 2006-01-20
PCT/US2006/046612 WO2007087015A1 (en) 2006-01-20 2006-12-06 Diagnostic and therapeutic targets for leukemia

Publications (3)

Publication Number Publication Date
JP2009524051A JP2009524051A (ja) 2009-06-25
JP2009524051A5 JP2009524051A5 (enExample) 2010-01-28
JP5167149B2 true JP5167149B2 (ja) 2013-03-21

Family

ID=38309541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551261A Expired - Fee Related JP5167149B2 (ja) 2006-01-20 2006-12-06 白血病の診断および治療ターゲット

Country Status (6)

Country Link
US (2) US8524467B2 (enExample)
EP (2) EP1974055A4 (enExample)
JP (1) JP5167149B2 (enExample)
AU (1) AU2006336552B2 (enExample)
CA (1) CA2623271A1 (enExample)
WO (1) WO2007087015A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
LT2836491T (lt) 2012-04-13 2017-03-27 Epizyme, Inc. Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma
CN105102431B (zh) 2012-10-15 2018-03-02 Epizyme股份有限公司 经取代的苯化合物
EP3027774B1 (en) * 2013-08-02 2020-07-15 Memorial Sloan-Kettering Cancer Center Methods for the detection and treatment of leukemias that are responsive to dot1l inhibition
CA2925889C (en) 2013-10-16 2020-09-29 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
EP3911418A1 (en) * 2019-01-15 2021-11-24 PTC Therapeutics, Inc. Method for treating an acute myeloid leukemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420328A (en) 1992-09-11 1995-05-30 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5525734A (en) 1994-06-22 1996-06-11 Affymax Technologies N.V. Methods for synthesizing diverse collections of pyrrolidine compounds
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
AU7829398A (en) * 1997-06-09 1998-12-30 University Of Southern California A cancer diagnostic method based upon dna methylation differences
US6555329B2 (en) * 2000-06-09 2003-04-29 Boehringer Ingelheim International Gmbh Method for identifying compounds altering higher-order chromatin-dependent chromosome stability
AU2002329784A1 (en) 2001-08-17 2003-03-03 Incyte Genomics, Inc. Molecules for disease detection and treatment
US7485414B2 (en) * 2002-08-30 2009-02-03 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
US7442685B2 (en) * 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
WO2006025832A1 (en) 2004-08-31 2006-03-09 University Of North Carolina At Chapel Hill Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia

Also Published As

Publication number Publication date
AU2006336552B2 (en) 2012-12-20
EP2730661A1 (en) 2014-05-14
JP2009524051A (ja) 2009-06-25
US8524467B2 (en) 2013-09-03
US20140044740A1 (en) 2014-02-13
WO2007087015A1 (en) 2007-08-02
EP1974055A4 (en) 2010-01-27
CA2623271A1 (en) 2007-08-02
AU2006336552A1 (en) 2007-08-02
EP1974055A1 (en) 2008-10-01
US20090061443A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
US9534259B2 (en) DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
US20140044740A1 (en) Diagnostic and Therapeutic Targets for Leukemia
Vogl et al. Neddylation inhibition impairs spine development, destabilizes synapses and deteriorates cognition
Korr et al. LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain
JP2010531662A (ja) Ｐ５３のモジュレータ及び癌の標的であるｔｒｉｍ２４（ｔｉｆ−１ａ）
EP1791973B1 (en) Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
Charó et al. Heterochromatin protein (HP) 1γ is not only in the nucleus but also in the cytoplasm interacting with actin in both cell compartments
JP2002516577A (ja) 哺乳動物ｃｈｋ１エフェクター細胞周期チェックポイントタンパク質キナーゼ物質及び方法
JP2003532428A (ja) 抗癌剤をスクリーニングするための酵素的アッセイ
US20040180349A1 (en) Diagnosis and treatment of cancer involving the notch pathway
JP2007282628A (ja) 抗癌剤のスクリーニング方法
KR20140046991A (ko) 메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
US20250320501A1 (en) Palmitoylation of the alternative amino terminus of the btk-c isoform controls subcellular distribution and signaling
Nuhu-Soso et al. Neuronal differentiation enhances a cytoplasmic pool of tousled-like kinase 2 (TLK2)
Zhao et al. Mono-ubiquitination of TopBP1 by PHRF1 enhances ATR activation and genomic stability
Sarkar Bookending the Germ Cell to Maternal Transition: Dynamics of Gene Regulation in Drosophila Oogenesis
US20040235001A1 (en) Regulatory poly(A) polymerase and uses thereof
JP2003533226A (ja) 神経細胞のセリンスレオニンプロテインキナーゼ
EP2250195B1 (en) Sulfatase enzymes
Jang Functional Characterization of Scaffold Protein Shoc2
EP1558274A2 (en) Methods for controlling proliferation of cells
Kilpatrick Elucidating the role of GODZ-mediated palmitoylation in controlling GABAergic inhibition
Peng Regulation and mechanism of NFBD1 and 53BP1 in mediating DNA damage responses
Pande Regulation of Runx Proteins in Human Cancers: A Dissertation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120724

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120824

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121221

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151228

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees